UK Islet Autoantibody Registry

Launched by UNIVERSITY OF OXFORD · Aug 8, 2025

Keywords

ClinConnect Summary

This study, called the UK Islet Autoantibody Registry, is looking at people who have certain markers in their blood called islet autoantibodies, which can indicate a higher risk of developing type 1 diabetes (T1D). T1D is a condition where the body’s immune system attacks the pancreas, stopping it from making insulin, a hormone that controls blood sugar. The research aims to better understand what it’s like to live with this risk, what kind of support and information people need, and how this affects their use of healthcare services. The study will also help doctors learn why some people with these markers go on to develop T1D while others do not.

People who have tested positive for one or more of these autoantibodies and are between 6 months and 70 years old may be eligible to join if they live in the UK and can give consent (or have a parent/guardian consent for young children). Participants will be added to a registry—a kind of database—that collects information about their health over time. They may also be informed if any new treatments become available to delay T1D and can choose to be contacted about future research studies that test ways to prevent or slow down the disease. This study offers a chance to contribute to important research that could improve care and support for people at risk of T1D.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female, aged 6 months - 70 years
• • IAb positive (≥ 1) to any of the following: insulin/GAD/IA2/ZnT8, confirmed in a reference laboratory.
• • Participant is willing and able to give informed consent for participation in the study (≥ 16 years old), or for \< 16 years, parental/guardian consent (plus assent, where appropriate)
• • Living in the UK
• • For ADDRESS-2 participants only: have taken part in a blood draw as part of ADDRESS-2
• • For the qualitative interviews: Have been living with (or is a parent/guardian of a child who has been living with) a positive IAb result for ≥ 6 months.
• Exclusion Criteria:
• • Ongoing subcutaneous insulin requirement